These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17145138)

  • 1. Is daytime insulin more physiologic and less atherogenic than bedtime insulin?
    Kanat M
    Med Hypotheses; 2007; 68(6):1228-32. PubMed ID: 17145138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and indirect effects of insulin on hepatic glucose production in diabetic depancreatized dogs during euglycemia.
    Gupta N; Park E; Sandhu H; Goh T; Tchipashvili V; Giacca A
    J Endocrinol; 2006 Sep; 190(3):695-702. PubMed ID: 17003270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin.
    Hamberg O
    Dan Med Bull; 1997 Jun; 44(3):225-41. PubMed ID: 9233544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations concerning the initial regimen and dose adjustments of insulin therapy for type 2 diabetes mellitus].
    Houweling ST; Timmerman GJ; Hoogstraten MF; Ubink-Veltmaat LJ; Verhoeven S; Bilo HJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1823-7. PubMed ID: 12382366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic effects of hyperglycaemia on glucose metabolism: implications for the development of new therapies.
    Yki-Järvinen H
    Diabet Med; 1997 Aug; 14 Suppl 3():S32-7. PubMed ID: 9272611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y; Guo XH; Vaz JA;
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insulin in the treatment of type 2 diabetes].
    Meyer L; Guerci B; Ziegler O; Drouin P
    Rev Prat; 1999 Jan; 49(1):51-5. PubMed ID: 9926717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux.
    Yoshii H; Lam TK; Gupta N; Goh T; Haber CA; Uchino H; Kim TT; Chong VZ; Shah K; Fantus IG; Mari A; Kawamori R; Giacca A
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1089-97. PubMed ID: 16390863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes.
    McCarty MF
    Med Hypotheses; 1999 May; 52(5):401-6. PubMed ID: 10416947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Physiopathology of postprandial hyperglycemia].
    Gin H
    Diabetes Metab; 2000 Jun; 26 Suppl 2():7-11. PubMed ID: 10975043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.